These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29623779)

  • 1. Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.
    De Wit S; Florence E; Vandekerckhove L; Vandercam B; Goffard JC; Van Wijngaerden E; Moutschen M; Demeester R; Thilakarathne P; Piryns H;
    Acta Clin Belg; 2018 Oct; 73(5):341-347. PubMed ID: 29623779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
    Huhn GD; Sigman A; Livak B
    Antivir Ther; 2015; 20(8):849-54. PubMed ID: 25881614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
    Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
    Lackey P; Mills A; Carpio F; Hsu R; DeJesus E; Pierone G; Henegar C; Fusco J; Fusco G; Wohlfeiler M
    Clin Drug Investig; 2017 Jan; 37(1):51-60. PubMed ID: 27587070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
    Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
    HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
    Larson KB; Cressey TR; Yogev R; Wiznia A; Hazra R; Jean-Philippe P; Graham B; Gonzalez A; Britto P; Carey VJ; Acosta EP;
    J Pediatric Infect Dis Soc; 2016 Jun; 5(2):131-7. PubMed ID: 27199469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study.
    Antinori A; Meraviglia P; Monforte Ad; Castagna A; Mussini C; Bini T; Gianotti N; Rusconi S; Colella E; Airoldi G; Mancusi D; Termini R
    Drug Des Devel Ther; 2016; 10():1589-603. PubMed ID: 27226708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
    Overton ET; Tebas P; Coate B; Ryan R; Perniciaro A; Dayaram YK; De La Rosa G; Baugh BP
    HIV Clin Trials; 2016 Mar; 17(2):72-7. PubMed ID: 26917112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice.
    Santos JR; Curran A; Navarro-Mercade J; Ampuero MF; Pelaez P; Pérez-Alvarez N; Clotet B; Paredes R; Moltó J
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):513-518. PubMed ID: 30909716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of virological response to therapy and resistance profile in treatment-experienced and naive HIV-1 infected Romanian patients receiving regimens containing darunavir boosted with ritonavir or cobicistat.
    Marin RC; Streinu-Cercel A; Moleriu LC; Bungau SG
    Biomed Pharmacother; 2022 Jun; 150():113077. PubMed ID: 35658217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
    Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
    Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation.
    Sahloff EG; Duggan JM
    Ann Pharmacother; 2019 Jan; 53(1):50-55. PubMed ID: 30047788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain.
    Pernas B; Grandal M; Tabernilla A; Cid P; Pértega S; Castro-Iglesias Á; Mena Á; Margusino L; Pedreira JD; Poveda E
    J Med Virol; 2016 Dec; 88(12):2125-2131. PubMed ID: 27218208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
    Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
    Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy.
    Mena Á; Cid P; Dueñas C; Garcinuño MÁ; Lorenzo JF; Margusino L; Quiñones M; Grande C; Rodríguez-Osorio I; Castro Á
    HIV Clin Trials; 2018 Oct; 19(5):197-201. PubMed ID: 30605006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day
    Di Cristo V; Adorni F; Maserati R; Annovazzi Lodi M; Bruno G; Maggi P; Volpe A; Vitiello P; Abeli C; Bonora S; Ferrara M; Cossu MV; Oreni ML; Colella E; Rusconi S
    HIV Res Clin Pract; 2020 Feb; 21(1):34-43. PubMed ID: 32129161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens.
    Armenia D; Di Carlo D; Maffongelli G; Borghi V; Alteri C; Forbici F; Bertoli A; Gori C; Giuliani M; Nicastri E; Zaccarelli M; Pinnetti C; Cicalini S; D'Offizi G; Ceccherini-Silberstein F; Mussini C; Antinori A; Andreoni M; Perno CF; Santoro MM
    HIV Med; 2017 Jan; 18(1):21-32. PubMed ID: 27353061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
    Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
    HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations.
    Gutierrez-Valencia A; Trujillo-Rodriguez M; Fernandez-Magdaleno T; Espinosa N; Viciana P; López-Cortés LF
    J Int AIDS Soc; 2018 Feb; 21(2):. PubMed ID: 29430854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.